Amgen Inc. has received a patent for its drug to treat anemia in patients undergoing kidney dialysis. However, a Cambridge, Mass., company has announced plans to go forward with the development of a competing product.
Amgen's patent for the drug, marketed under the name Epogen, provides protection against the unauthorized making, importation, use or sale of recombinant erythropoietin (EPO) in the United States.
The Thousand Oaks biotechnology company said it already has patents covering DNA and host cells and the manufacturing process for recombinant EPO.
However, Transkaryotic Therapies Inc. said it will sell shares in an initial public offering and expects to begin human tests of its erythropoietin product in the first half of next year.